Overall, CAR T cell therapy beyond oncology is promising but remains preliminary, requiring standardized reporting, long-term safety monitoring, scalable manufacturing, and carefully defined risk–benefit thresholds.
Abstract
Background: Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of select hematologic malignancies and is increasingly being explored for non-oncological indications, including autoimmune diseases and persistent infectious diseases. This systematic review synthesized current evidence on CAR T cell and CAR-Treg approaches beyond oncology, with emphasis on therapeutic targets, translational and clinical outcomes, safety, and implementation barriers. Methods: The review followed PRISMA 2020 guidelines. PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, and major trial registries were searched for studies published from 1 January 2010 to 31 March 2026. Eligible studies included clinical, preclinical, and translational investigations of CAR T cell or CAR-Treg strategies in autoimmune or infectious diseases. Results: Because of heterogeneity in disease indications, CAR constructs, endpoints, and study designs, findings were synthesized descriptively. The strongest early clinical signals were observed with B cell-directed CAR T cell therapy for severe, refractory autoimmune diseases, particularly systemic lupus erythematosus, systemic sclerosis, and inflammatory myopathies. Infectious disease applications, mainly HIV and hepatitis B, showed preliminary safety, persistence, and partial antiviral activity, but durable pathogen eradication remains unproven. Conclusion: Overall, CAR T cell therapy beyond oncology is promising but remains preliminary, requiring standardized reporting, long-term safety monitoring, scalable manufacturing, and carefully defined risk–benefit thresholds. Human clinical evidence was interpreted separately from preclinical and mechanistic evidence, and clinical conclusions were based primarily on human studies.
Based on the current available evidence, CAR-T therapy appears to have a generally manageable safety profile in autoimmune diseases, supporting its potential as a promising treatment option for patients with relapsed or refractory autoimmune diseases.
Yan-Xia Xie, Yang Liu, Xiao-Yuan Chen et al.· Immunologic research· 1 citation
Cellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD and robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.
F. Suárez-Trujillo, Theodore S. Steiner, J. P. Gisbert et al.· Frontiers in Immunology· 0 citations
This review of established and emerging targeted therapies for SLE, including CAR T cell therapy, with emphasis on mechanisms, efficacy, safety, regulatory status, and clinical roles, finds that approaches differ in regulatory status and clinical readiness.
Filip Chodań, Estera Sośniecka, Olga Klimczak et al.· Archiv Euromedica· 0 citations
Introduction Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematologic malignancies, prompting its exploration in solid tumors. This systematic review and meta-analysis aimed to evaluate the safety and feasibility of CAR-T therapy for solid tumor treatment. Methods We systematically...
Kun-Peng Wang, Lian Li, Zhang-Neng Yu et al.· Frontiers in Immunology· 0 citations
Current challenges in solid tumour treatment are examined through evidence from clinical trials, highlighting key obstacles such as antigen heterogeneity, the immunosuppressive tumour microenvironment, poor cellular trafficking, and treatment-related failures that have informed the development of next-generation CAR co...
A. Justiz-Vaillant, Sachin Soodeen, Rodolfo Arozarena-Fundora et al.· Frontiers in Molecular Medic...· 3 citations
Within this limited early-phase evidence base, no severe toxicities attributable to non-viral platforms were reported, and the evidence identifies knowledge gaps warranting prospective investigation.
Favio Varón Suárez, J. Moreno, Oriana Arias-Valderrama et al.· Frontiers in Immunology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.